With recent patents granted in Australia, Canada, Europe, and the U.S., Sabinsa’s intellectual property portfolio now includes 308 separate patents granted around the world.
 
The company’s patent portfolio includes composition, use and process patents. Many relate to varying aspects of category-leading ingredients such as LactoSpore, DigeZyme, and Curcumin C3 Complex. Others are for relatively new, up and coming ingredients such as Nigellin and Sabroxy.
 
“I’m very proud that Sabinsa has reached the milestone of over 300 patented grants worldwide, and more are coming,” said Dr. Muhammed Majeed, founder and chairman of the Sami-Sabinsa Group. “Our motto ‘Our Innovation is your Answer’ truly reflects the new products, nutritional supplements and formulations we develop in accordance with global standards to cater to the growing needs of the industry, and consumers.”  
 
Sabinsa’s IP portfolio started with the granting of U.S. patent no. 5536506, issued in July of 1996 for its extract of black pepper, BioPerine, for improving gastrointestinal absorption of nutrients.
 
Black pepper is a common spice ingredient in the Indian diet and used in the Ayurvedic system of medicine. However, knowledge of the therapeutic use of black pepper was still limited. With this invention of black pepper extract and published research, Sabinsa helped many companies develop formulations to improve the absorption of vital nutrients.
 
This achievement also set a standard for researching nutraceutical ingredients to support products in the marketplace. Significant company growth followed as Sabinsa developed, researched, and launched ingredients like Curcumin C3 Complex, Citrin, ForsLean, LivLonga, LactoSpore, and others. The company also invented and patented products for skin and hair care, anticipating the trend for natural ingredients in that market.
 
Recent patents Sabinsa has been granted are for new products Nigellin and Sabroxy.  Nigellin is a product enriched with thymoquinone and thymohydroquinone, isolated from the seeds of Nigella sativa (black cumin), which has many beneficial properties.
 
Nigellin is formulated to further enrich the therapeutic benefits of black cumin seeds. This patented composition (US10945969) also earned a U.S. patent for its use in decreasing blood glucose levels by inhibiting the enzyme involved in carbohydrate digestion and absorption – α-glucosidase, and increasing glucose uptake by the cells (US10881623), indicating a potential use in managing diabetes and related conditions.
 
One of Sabinsa’s newest products, Sabroxy, is a natural solution for better management of mental and cognitive health. Formulated from the bark of Oroxylum indicum and standardized to contain oroxylin A, baicalein and chrysin, this patented composition (US10555982) can help in maintaining good cognitive and mental health, the company said. The composition also earned another patent for managing and alleviating symptoms of neurotoxicity due to hyperglycemia and chemotherapeutics (US10894029). In addition to its neuroprotective functions, the composition is effective in reducing epileptic seizures (patent pending) and decreasing triglyceride levels in the blood (US10959980).
 
In addition to IP supporting its newest ingredients, Sabinsa’s flagship probiotic LactoSpore was also awarded new patents. LactoSpore was effective in inhibiting infections related to Helicobacter pylori, along with Saberry (Amla, or Indian Gooseberry). This invention was granted a patent in the U.S. (US10792295). In addition, a U.S. patent was awarded for the ability of LactoSpore to reduce intestinal gas (flatulence) and in inhibiting gas producing microbes (US 10806760). 
 
The extracellular metabolite of LactoSpore trademarked as LactoSporin, purified from the culture supernatant of the probiotic, was also granted a patent for its use in preventing the formation of aging signs on the skin (US10966919).